ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose

Related Keywords

Spain ,Australia ,Madrid ,Zurich ,Züsz ,Switzerland ,United States ,Schroder Adveq ,Christoph Renner ,Ludger Wess Ines Regina Buth ,Company Contact ,Mission Biocapital ,Zurich Area ,Immunos Therapeutics ,Samsara Biocapital ,Lightspeed Venture Partners ,Pfizer Ventures ,Biomed Partners ,Ludger Wess ,Business ,